Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 4/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858125 | 0.89 | CDK8 (0.52) | CDK8PAK1AXLAAK1CHEK1 | |
| SCHEMBL442522 | 0.88 | CDK8 (0.46) | CDK8CYP2C9PAK1AXLAAK1 | |
| SCHEMBL857781 | 0.86 | AAK1 (0.50) | CDK8CYP2C9CYP3A4PAK1AXL | |
| SCHEMBL17859213 | 0.85 | CYP2C9 (0.42) | CDK8CYP2C9CYP3A4PAK1AXL | |
| SCHEMBL4014801 | 0.84 | AXL (0.60) | CDK8CYP2C9CYP3A4PAK1AXL | |
| SCHEMBL856967 | 0.84 | AXL (0.59) | CDK8CYP2C9PAK1AXLAAK1 | |
| SCHEMBL856944 | 0.84 | CDK8 (0.46) | CDK8CYP3A4PAK1AXLAAK1 | |
| SCHEMBL416109 | 0.82 | CYP2C9 (0.52) | CYP2C9CYP3A4PAK1AXLAAK1 | |
| SCHEMBL858503 | 0.82 | CDK8 (0.48) | CDK8CYP2C9PAK1AXL | |
| SCHEMBL857771 | 0.81 | AAK1 (0.48) | CDK8PAK1AXLAAK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | claimed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2395004-B1 | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors | PLEXXIKON INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | CDK8 185/4885CYP2C9 4869/4885CYP3A4 4851/4885 |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | CDK8 1633/4885CYP2C9 4784/4885CYP3A4 4802/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885CYP2C9 4746/4885CYP3A4 4658/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885CYP2C9 4746/4885CYP3A4 4658/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885CYP2C9 4746/4885CYP3A4 4658/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | CDK8 2155/4885CYP2C9 4812/4885CYP3A4 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.